Pharmaceutical composition for preventing osteoporosis and preparation process thereof
By combining saccharomycene flavonoid extract, chondroitin sulfate and collagen peptide with sodium alginate hydrogel to form a bone-targeted pharmaceutical composition, the stability and biological of the drugs in the gastrointestinal environment in the prior art are solved. The problem of low utilization has achieved effective prevention of osteoporosis.
Patent Information
- Application Number
- CN202411140468.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-22
AI Technical Summary
Existing osteoporosis treatment drugs have low stability and bioavailability in the gastrointestinal environment, and lack bone targeting, making it difficult to effectively target bone tissue.
Sophora bei flavonoid extract, chondroitin sulfate and collagen peptide were used to combine with sodium alginate hydrogel, and grafting it on the sodium alginate carrier through targeted intermediates to form a bone-targeted drug composition to improve the stability of the drug. sex and bioavailability.
It improves the stability and bioavailability of flavonoid extracts, enhances bone targeting, promotes osteoblast proliferation and new bone formation, and effectively prevents osteoporosis.
Smart Images

Figure CN118987158A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of preparation of articular cartilage repair materials, and in particular to a pharmaceutical composition for preventing osteoporosis and a preparation process thereof. Background Art
[0002] Osteoporosis (OP) is a systemic bone disease characterized by decreased bone mass, damaged bone tissue microstructure, increased bone brittleness, and susceptibility to fractures. The causes of osteoporosis are complex and diverse, including the interaction between endocrine, nutritional status, genetics, physiological and immune factors. Increased bone resorption and decreased bone formation lead to an imbalance in bone coupling. The regulation of bone formation and bone resorption mediated by osteoblasts and osteoclasts is a complex biological process. Bone is constantly remodeling, and formation and resorption need to maintain a close balance to maintain bone homeostasis. The imbalance in bone homeostasis between osteoblast bone formation and osteoclast bone resorption is the root cause of osteoporosis.
[0003] At present, the commonly used drug administration methods for the treatment and prevention of osteoporosis are generally oral preparations and injections. Oral delivery is a route of administration that uses the physiological cavity of the human body for systemic treatment. It has the characteristics of non-invasiveness, low cost and convenient administration. However, the complex gastrointestinal physiological environment (acidic environment in the stomach, a large amount of digestive enzymes and intestinal mucus / mucosal barriers, etc.) can lead to reduced stability and bioavailability of oral drugs. In addition, most oral drugs are not bone-targeted and are difficult to target bone tissue and bone cells, which further reduces the bioavailability of drugs for the treatment and prevention of osteoporosis.
[0004] Therefore, there is a need for a pharmaceutical composition for preventing osteoporosis with good stability and bone targeting and a preparation process thereof to improve the bioavailability of the drug. Summary of the invention
[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a pharmaceutical composition for preventing osteoporosis and a preparation process thereof.
[0006] A preparation process of a pharmaceutical composition for preventing osteoporosis comprises the following steps:
[0007] S1: Preparation of Sophora japonica flavonoids extract
[0008] The sophora japonica seed is washed, dried, and crushed, and then added to a methanol solution, and then hydrochloric acid is added to perform ultrasonic assisted reflux extraction, and after filtering, the filter residue is repeatedly extracted once, and the filtrate is combined and evaporated and concentrated to obtain the sophora japonica seed flavonoids extract;
[0009] S2: Pretreatment of sturgeon
[0010] The sturgeon segments are thawed, the meat is removed, the head, spinal cord and fin cartilage are taken out, and they are immersed in 80-100°C water for 5-10 minutes, then taken out and cooled to 30-40°C, the muscles, fat and other connective tissues remaining on the head, spinal cord and fin cartilage are removed, and then they are minced with a meat grinder, put into water and stirred, and sieved, washed and dried to obtain pre-treated aggregates;
[0011] S3: Preparation of chondroitin sulfate and collagen peptides
[0012] The pretreated aggregate is mixed with deionized water for grinding, and then heated. After cooling, sodium carbonate is added to adjust the pH, and then alkaline protease, papain and bromelain are added in sequence for enzymolysis. After the enzymes are inactivated, chondroitin sulfate and collagen peptides are obtained by filtering, ultrafiltration and freeze drying.
[0013] S4: Preparation of targeted intermediates
[0014] Mixing stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide, heating and dissolving them to prepare a mixed solution, then dissolving tetracycline hydrochloride to prepare a tetracycline hydrochloride solution, then adding the tetracycline hydrochloride solution to the mixed solution, reacting, dialyzing, centrifuging, washing and drying to obtain a targeted intermediate;
[0015] S5: Preparation of pharmaceutical composition
[0016] The targeting intermediate is dissolved in ethanol to prepare a targeting intermediate solution, sodium alginate is dissolved in ultrapure water, calcium chloride solution is added and stirred to prepare a sodium alginate mixed solution, the sophora japonica flavonoids extract, the chondroitin sulfate and the collagen peptide are added to the sodium alginate mixed solution, and the targeting intermediate solution is added, the mixture is heated and stirred, and then the gelatin liquid is separated, freeze-dried and ground to obtain a pharmaceutical composition.
[0017] Furthermore, S1 specifically includes the following steps:
[0018] S1.1: Wash and dry the Sophora japonica seeds, and then place them in a grinder to fully grind them to obtain Sophora japonica seeds powder;
[0019] S1.2: Add the above-mentioned Sophora japonica powder to 60% methanol solution at a solid-liquid ratio of 1g: (90-100)mL, stir and mix evenly, and then add hydrochloric acid at 0.01-0.03mmol / L to obtain an extract;
[0020] S1.3: The above extract is heated to 60-70°C for 20-30 minutes and then subjected to ultrasonic-assisted reflux extraction for 1-2 hours. After cooling, it is filtered and the residue is repeatedly extracted once. The filtrates are combined and the combined filtrates are placed in a rotary evaporator for evaporation and concentration to obtain the sophora japonica flavonoids extract.
[0021] Furthermore, S3 specifically includes the following steps:
[0022] S3.1: Mix the pretreated aggregate obtained in step S2 with deionized water in a mass ratio of 1:(4-6) and grind into a slurry, then heat at 90-100°C for 20-30min, and when the temperature drops to 25-30°C, add sodium carbonate to adjust the pH to 8-9 to obtain a mixed slurry;
[0023] S3.2: add alkaline protease to the mixed slurry, heat at 40-45°C for 1-2h, then add papain, heat at 45-50°C for 1-2h, then add bromelain, heat at 45-50°C for 1-2h, then heat to 90-95°C, inactivate the enzyme for 20-30min, and obtain an enzymolysis solution;
[0024] S3.3: The above enzymatic hydrolysate is filtered, and the filtrate is ultrafiltered using a hollow fiber membrane with a molecular weight cutoff of 10,000 Da. The retained portion is freeze-dried to obtain chondroitin sulfate, and the permeate is freeze-dried to obtain collagen peptides.
[0025] Furthermore, S4 specifically includes the following steps:
[0026] S4.1: Add stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide into a reactor at a solid-liquid ratio of (1.4-2) g: (1.5-1.9) g: 1 g: (130-150) mL, heat and stir at 40-50 ° C for 1-2 h to fully dissolve, and then keep warm for 20-30 min to obtain a mixed solution;
[0027] S4.2: Dissolve tetracycline hydrochloride in N,N-dimethylformamide at a solid-liquid ratio of 1 g:(20-30) mL to obtain a tetracycline hydrochloride solution;
[0028] S4.3: Add the above-mentioned tetracycline hydrochloride to the above-mentioned mixed solution, react for 20-24 hours under a nitrogen atmosphere, and then place it in a dialysis bag for dialyzing for 48-50 hours. Take out the suspension in the dialysis bag and place it in a centrifuge. Centrifuge at a rate of 4000-5000r / min for 8-10min, collect the precipitate, wash and dry it to obtain a targeted intermediate.
[0029] Furthermore, S5 specifically includes the following steps:
[0030] S5.1: Add the targeted intermediate prepared in step S4.3 to ethanol at a solid-liquid ratio of 1 g: (10-12) mL, and stir until completely dissolved to obtain a targeted intermediate solution;
[0031] S5.2: Dissolve sodium alginate in ultrapure water at a solid-liquid ratio of 1 g: (60-70) mL, add calcium chloride solution, and perform ultrasonic stirring until it becomes viscous to obtain a sodium alginate mixed solution;
[0032] S5.3: Add the flavonoids extract of Sophora japonica obtained in step S1.3, chondroitin sulfate and collagen peptide obtained in step S3.3 to the above-mentioned sodium alginate mixed solution, stir and mix evenly, then add the above-mentioned targeted intermediate solution at a mass ratio of targeted intermediate to sodium alginate of 1:(8-12), heat and stir at 30-40°C for 12-14h, separate the gel solution, and obtain a composite gel;
[0033] S5.4: Place the above composite gel in a freeze dryer for freeze drying, and then place it in a grinder for grinding to obtain a pharmaceutical composition.
[0034] Furthermore, the amount of alkaline protease is 200 U / g, the amount of papain is 100 U / g, and the amount of bromelain is 30 U / g.
[0035] Furthermore, the mass ratio of tetracycline hydrochloride to stearic acid is (1.3-1.5):1.
[0036] Furthermore, the concentration of the calcium chloride solution is 1-3%, and the volume ratio of the calcium chloride solution to ultrapure water is 1:(25-35).
[0037] Furthermore, the mass ratio of the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide is (6-8):(3-5):1, and the mass ratio of the sophora japonica flavonoids extract to sodium alginate is 1:(20-30).
[0038] A pharmaceutical composition for preventing osteoporosis, which is prepared by any of the above-mentioned preparation processes for a pharmaceutical composition for preventing osteoporosis.
[0039] Compared with the prior art, the present invention has the following beneficial effects:
[0040] 1. The present invention first dissolves sodium alginate in ultrapure water, adds calcium chloride as a cross-linking agent, stirs and cross-links to form a hydrogel, then adds the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide, and fully mixes them to load the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide in the sodium alginate hydrogel. Sodium alginate is used as a carrier of the sophora japonica flavonoids extract, an active ingredient for preventing osteoporosis, so as to effectively improve the stability of the sophora japonica flavonoids extract, thereby improving the bioavailability of the sophora japonica flavonoids extract.
[0041] 2. The present invention prepares a targeted intermediate with bone targeting effect by dissolving stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenzotriazole in N,N-dimethylformamide to prepare a mixed solution, dissolving tetracycline hydrochloride in N,N-dimethylformamide to prepare a tetracycline hydrochloride solution, and then adding the tetracycline hydrochloride solution to the mixed solution for reaction. After the bone targeting intermediate is grafted on the sodium alginate hydrogel, the bone targeting of the sodium alginate drug-loaded hydrogel can be improved, and the problem of poor specificity of the hydrogel loaded with the components such as the sophora japonica flavonoids extract can be corrected, thereby enhancing the osteoblast differentiation and further improving the bioavailability of the sophora japonica flavonoids extract.
[0042] 3. The sophora japonica flavonoids extract of the present invention can intervene in the Wnt / β-catenin signaling pathway to regulate the amount of β-catenin and the formation of the β-catenin-TCF / LEF complex, promote the production of BMP bone morphogenetic protein and osteoblast proliferation and differentiation, and inhibit osteoclast formation, while chondroitin sulfate can help maintain the lubricity and elasticity of joints, affect the metabolism of bone cells, protect bone tissue, increase bone mineral content and bone density, promote osteoblast proliferation and new bone formation, and the compounding of the sophora japonica flavonoids extract and chondroitin sulfate has a synergistic effect and prevents the risk of osteoporosis. In addition, the addition of collagen peptides can interact with chondroitin sulfate to help accelerate the regeneration of damaged cartilage. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] The accompanying drawings, which are incorporated herein and constitute a part of the specification, illustrate embodiments of the present disclosure and, together with the description, further serve to explain the principles of the present disclosure and to enable those skilled in the relevant art to make and use the present disclosure.
[0044] Figure 1 This is a process flow chart of the preparation of a pharmaceutical composition for preventing osteoporosis adopted in an embodiment of the present invention;
[0045] Figure 2 This is a cumulative drug release percentage curve diagram of Example 1 of the present invention;
[0046] Figure 3The fluorescence distribution diagram in rat femur of Example 1 and Comparative Example 2 of the present invention. DETAILED DESCRIPTION
[0047] A pharmaceutical composition for preventing osteoporosis and its preparation process provided by the present invention are described in detail below in conjunction with the accompanying drawings and specific examples.
[0048] Example 1
[0049] A preparation process of a pharmaceutical composition for preventing osteoporosis, such as Figure 1 As shown, the following steps are included:
[0050] S1: Preparation of Sophora japonica flavonoids extract
[0051] The sophora japonica seed is washed and dried, and then placed in a grinder for full grinding to obtain sophora japonica seed powder, and then the sophora japonica seed powder is added to a 60% methanol solution at a solid-liquid ratio of 1g:90mL, and after stirring and mixing evenly, hydrochloric acid is added at 0.01mmol / L to obtain an extract, and then the extract is heated to 60°C for reflux extraction for 20min, and then ultrasonic-assisted reflux extraction for 1h, and after cooling, it is filtered, and the filter residue is repeatedly extracted once, the filtrate is combined and the combined filtrate is placed in a rotary evaporator for evaporation and concentration to obtain a sophora japonica seed flavonoid extract;
[0052] S2: Pretreatment of sturgeon
[0053] The sturgeon segments were thawed, the meat was removed, the head, spinal cord and fin cartilage were taken out, and they were immersed in 80℃ water for 5 minutes, then taken out and cooled to 30℃, the muscles, fat and other connective tissues remaining on the head, spinal cord and fin cartilage were removed, and then minced with a meat grinder, put into water and stirred, and sieved, washed and dried to obtain pre-treated aggregates;
[0054] S3: Preparation of chondroitin sulfate and collagen peptides
[0055] The pretreated aggregate obtained in step S2 is mixed with deionized water in a mass ratio of 1:4 and ground into a slurry, and then heated at 90°C for 20 minutes. When the temperature drops to 25°C, sodium carbonate is added to adjust the pH to 8 to obtain a mixed slurry. Subsequently, alkaline protease is added to the mixed slurry, and the mixture is heated at 40°C for enzymolysis for 1 hour. Papain is added and the mixture is heated at 45°C for enzymolysis for 1 hour. Bromelain is then added and the mixture is heated at 45°C for enzymolysis for 1 hour. The mixture is then heated to 90°C and the enzyme is inactivated for 20 minutes to obtain an enzymolysis solution, wherein the amount of alkaline protease is 200U / g, the amount of papain is 100U / g, and the amount of bromelain is 30U / g. Finally, the enzymolysis solution is filtered, and the filtrate is ultrafiltered using a hollow fiber membrane with a molecular weight cutoff of 10,000Da, the retained portion is freeze-dried to obtain chondroitin sulfate, and the permeate is freeze-dried to obtain collagen peptides.
[0056] S4: Preparation of targeted intermediates
[0057] Stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide were added to the reactor at a solid-liquid ratio of 1.4g:1.5g:1g:130mL, heated and stirred at 40°C for 1h to fully dissolve, and then kept warm for 20min to obtain a mixed solution for standby use, and then tetracycline hydrochloride was dissolved in N,N-dimethylformamide at a solid-liquid ratio of 1g:20mL to obtain a tetracycline hydrochloride solution, and then tetracycline hydrochloride was added to the above mixed solution, reacted for 20h under a nitrogen atmosphere, and then placed in a dialysis bag for 48h, the suspension in the dialysis bag was taken out and placed in a centrifuge, centrifuged at a rate of 4000r / min for 8min, the precipitate was collected, washed and dried to obtain a targeted intermediate, wherein the mass ratio of tetracycline hydrochloride to stearic acid was 1.3:1;
[0058] S5: Preparation of pharmaceutical composition
[0059] The targeted intermediate prepared in step S4 is added to ethanol at a solid-liquid ratio of 1g:10mL, stirred until completely dissolved, to obtain a targeted intermediate solution for standby use, and then sodium alginate is dissolved in ultrapure water at a solid-liquid ratio of 1g:60mL, and then calcium chloride solution is added, and ultrasonic stirring is performed until it becomes viscous to obtain a sodium alginate mixed solution, wherein the concentration of the calcium chloride solution is 1%, and the volume ratio of the calcium chloride solution to the ultrapure water is 1:25. Subsequently, the sophora japonica flavonoids extract prepared in step S1, the chondroitin sulfate prepared in step S3, and the collagen The protein peptide is added to the above-mentioned sodium alginate mixed solution, stirred and mixed evenly, and then the above-mentioned targeted intermediate solution is added, and heated and stirred at 30°C for 12 hours. The gel solution is separated to obtain a composite gel, wherein the mass ratio of the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide is 6:3:1, the mass ratio of the sophora japonica flavonoids extract to sodium alginate is 1:20, and the mass ratio of the targeted intermediate to sodium alginate is 1:8. Finally, the composite gel is placed in a freeze dryer for freeze drying, and then placed in a grinder for grinding to obtain a pharmaceutical composition.
[0060] Example 2
[0061] A preparation process of a pharmaceutical composition for preventing osteoporosis, such as Figure 1 As shown, the following steps are included:
[0062] S1: Preparation of Sophora japonica flavonoids extract
[0063] The sophora japonica seed is washed and dried, and then placed in a grinder for full grinding to obtain sophora japonica seed powder, and then the sophora japonica seed powder is added to a 60% methanol solution at a solid-liquid ratio of 1g:95mL, and after stirring and mixing evenly, hydrochloric acid is added at 0.02mmol / L to obtain an extract, and then the extract is heated to 65°C for reflux extraction for 25min, and then ultrasonic-assisted reflux extraction for 1.5h, and after cooling, it is filtered, and the filter residue is repeatedly extracted once, the filtrate is combined and the combined filtrate is placed in a rotary evaporator for evaporation and concentration to obtain a sophora japonica seed flavonoid extract;
[0064] S2: Pretreatment of sturgeon
[0065] The sturgeon segments were thawed, the meat was removed, the head, spinal cord and fin cartilage were taken out, and the segments were immersed in 90°C water for 8 minutes, then taken out and cooled to 35°C, the muscles, fat and other connective tissues remaining on the head, spinal cord and fin cartilage were removed, and then minced with a meat grinder, put into water and stirred, and sieved, washed and dried to obtain pre-treated aggregates;
[0066] S3: Preparation of chondroitin sulfate and collagen peptides
[0067] The pretreated aggregate obtained in step S2 is mixed with deionized water in a mass ratio of 1:5 and ground into a slurry, and then heated at 95°C for 25 minutes. When the temperature drops to 28°C, sodium carbonate is added to adjust the pH to 8.5 to obtain a mixed slurry. Subsequently, alkaline protease is added to the mixed slurry, and the mixture is heated at 43°C for enzymolysis for 1.5 hours. Papain is added and the mixture is heated at 48°C for enzymolysis for 1.5 hours. Bromelain is added and the mixture is heated at 48°C for enzymolysis for 1.5 hours. The mixture is then heated to 93°C and the enzyme is inactivated for 25 minutes to obtain an enzymolysis solution, wherein the amount of alkaline protease is 200U / g, the amount of papain is 100U / g, and the amount of bromelain is 30U / g. Finally, the enzymolysis solution is filtered, and the filtrate is ultrafiltered using a hollow fiber membrane with a molecular weight cutoff of 10,000Da, the retained portion is freeze-dried to obtain chondroitin sulfate, and the permeate is freeze-dried to obtain collagen peptides.
[0068] S4: Preparation of targeted intermediates
[0069] Stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide were added to the reactor at a solid-liquid ratio of 1.7g:1.7g:1g:140mL, heated and stirred at 40-50°C for 1.5h to fully dissolve, and then kept warm for 25min to obtain a mixed solution for standby use, and then tetracycline hydrochloride was dissolved in N,N-dimethylformamide at a solid-liquid ratio of 1g:25mL to obtain a tetracycline hydrochloride solution, and then tetracycline hydrochloride was added to the above mixed solution, reacted for 22h under a nitrogen atmosphere, and then placed in a dialysis bag for 49h, the suspension in the dialysis bag was taken out and placed in a centrifuge, centrifuged at a rate of 4500r / min for 9min, the precipitate was collected, washed and dried to obtain a targeted intermediate, wherein the mass ratio of tetracycline hydrochloride to stearic acid was 1.4:1;
[0070] S5: Preparation of pharmaceutical composition
[0071] The targeted intermediate prepared in step S4 was added to ethanol at a solid-liquid ratio of 1g:11mL, and stirred until completely dissolved to obtain a targeted intermediate solution for standby use. Then, sodium alginate was dissolved in ultrapure water at a solid-liquid ratio of 1g:65mL, and calcium chloride solution was added and ultrasonically stirred until it became viscous to obtain a sodium alginate mixed solution, wherein the concentration of the calcium chloride solution was 2%, and the volume ratio of the calcium chloride solution to ultrapure water was 1:30. Subsequently, the sophora japonica flavonoids extract prepared in step S1, the chondroitin sulfate prepared in step S3, and the collagen protein The peptide is added to the above-mentioned sodium alginate mixed solution, stirred and mixed evenly, and then the above-mentioned targeted intermediate solution is added, and heated and stirred at 35°C for 13 hours. The gel solution is separated to obtain a composite gel, wherein the mass ratio of the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide is 7:4:1, the mass ratio of the sophora japonica flavonoids extract to sodium alginate is 1:25, and the mass ratio of the targeting intermediate to sodium alginate is 1:10. Finally, the composite gel is placed in a freeze dryer for freeze drying, and then placed in a grinder for grinding to obtain a pharmaceutical composition.
[0072] Example 3
[0073] A preparation process of a pharmaceutical composition for preventing osteoporosis, such as Figure 1 As shown, the following steps are included:
[0074] S1: Preparation of Sophora japonica flavonoids extract
[0075] The sophora japonica seed is washed and dried, and then placed in a grinder for full grinding to obtain sophora japonica seed powder, and then the sophora japonica seed powder is added to a 60% methanol solution at a solid-liquid ratio of 1g:100mL, and after stirring and mixing evenly, hydrochloric acid is added at 0.03mmol / L to obtain an extract, and then the extract is heated to 70°C for reflux extraction for 30min, and then ultrasonic-assisted reflux extraction for 2h, and after cooling, it is filtered, and the filter residue is repeatedly extracted once, the filtrate is combined and the combined filtrate is placed in a rotary evaporator for evaporation and concentration to obtain a sophora japonica seed flavonoid extract;
[0076] S2: Pretreatment of sturgeon
[0077] The sturgeon segments are thawed, the meat is removed, the head, spinal cord and fin cartilage are taken out, and they are immersed in 100°C water for 10 minutes, then taken out and cooled to 40°C, the muscles, fat and other connective tissues remaining on the head, spinal cord and fin cartilage are removed, and then they are minced with a meat grinder, put into water and stirred, and sieved, washed and dried to obtain pre-treated aggregates;
[0078] S3: Preparation of chondroitin sulfate and collagen peptides
[0079] The pretreated aggregate obtained in step S2 is mixed with deionized water in a mass ratio of 1:6 and ground into a slurry, and then heated at 100°C for 30 minutes. When the temperature drops to 30°C, sodium carbonate is added to adjust the pH to 9 to obtain a mixed slurry. Subsequently, alkaline protease is added to the mixed slurry, and the mixture is heated at 45°C for enzymolysis for 2 hours. Papain is added and the mixture is heated at 50°C for enzymolysis for 2 hours. Bromelain is then added and the mixture is heated at 50°C for enzymolysis for 2 hours. The mixture is then heated to 95°C and the enzyme is inactivated for 30 minutes to obtain an enzymolysis solution, wherein the amount of alkaline protease is 200U / g, the amount of papain is 100U / g, and the amount of bromelain is 30U / g. Finally, the enzymolysis solution is filtered, and the filtrate is ultrafiltered using a hollow fiber membrane with a molecular weight cutoff of 10,000Da. The retained portion is freeze-dried to obtain chondroitin sulfate, and the permeate is freeze-dried to obtain collagen peptides.
[0080] S4: Preparation of targeted intermediates
[0081] Stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide were added to the reactor at a solid-liquid ratio of 2g:1.9g:1g:150mL, heated and stirred at 40-50°C for 2h to fully dissolve, and then kept warm for 20-30min to obtain a mixed solution for standby use, and then tetracycline hydrochloride was dissolved in N,N-dimethylformamide at a solid-liquid ratio of 1g:30mL to obtain a tetracycline hydrochloride solution, and then tetracycline hydrochloride was added to the above mixed solution, reacted under a nitrogen atmosphere for 24h, and then placed in a dialysis bag for 50h, the suspension in the dialysis bag was taken out and placed in a centrifuge, centrifuged at a rate of 5000r / min for 10min, the precipitate was collected, washed and dried to obtain a targeted intermediate, wherein the mass ratio of tetracycline hydrochloride to stearic acid was 1.5:1;
[0082] S5: Preparation of pharmaceutical composition
[0083] The targeted intermediate prepared in step S4 was added to ethanol at a solid-liquid ratio of 1g:12mL, and stirred until completely dissolved to obtain a targeted intermediate solution for standby use. Then, sodium alginate was dissolved in ultrapure water at a solid-liquid ratio of 1g:70mL, and calcium chloride solution was added and ultrasonically stirred until it became viscous to obtain a sodium alginate mixed solution, wherein the concentration of the calcium chloride solution was 3%, and the volume ratio of the calcium chloride solution to ultrapure water was 1:35. Subsequently, the sophora japonica flavonoids extract prepared in step S1, the chondroitin sulfate prepared in step S3, and the collagen protein The peptide is added to the above-mentioned sodium alginate mixed solution, stirred and mixed evenly, and then the above-mentioned targeted intermediate solution is added, and heated and stirred at 40°C for 14 hours. The gel solution is separated to obtain a composite gel, wherein the mass ratio of the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide is 8:5:1, the mass ratio of the sophora japonica flavonoids extract to sodium alginate is 1:30, and the mass ratio of the targeting intermediate to sodium alginate is 1:12. Finally, the composite gel is placed in a freeze dryer for freeze drying, and then placed in a grinder for grinding to obtain a pharmaceutical composition.
[0084] Comparative Example 1
[0085] The difference between this comparative example and Example 1 is that steps S4 and S5 are removed, and the sophora japonica flavonoids extract, chondroitin sulfate and collagen peptide are directly mixed in a mass ratio of 6:3:1 to prepare a pharmaceutical composition.
[0086] Comparative Example 2
[0087] This comparative example is substantially the same as Example 1, except that step S4 is removed, and the targeted intermediate in step S5 is removed.
[0088] Comparative Example 3
[0089] This comparative example is basically the same as Example 1, except that the chondroitin sulfate in step S5 is replaced by an equal amount of the sophora japonica flavonoids extract.
[0090] Comparative Example 4
[0091] This comparative example is basically the same as Example 1, except that the sophora japonica flavonoids extract in step S5 is replaced with an equal amount of chondroitin sulfate.
[0092] Comparative Example 5
[0093] This comparative example is basically the same as Example 1, except that the chondroitin sulfate in step S5 is replaced by an equal amount of collagen peptide.
[0094] Comparative Example 6
[0095] This comparative example is basically the same as Example 1, except that the collagen peptide in step S5 is replaced by an equal amount of chondroitin sulfate.
[0096] Experimental example
[0097] Experiment 1:
[0098] 200 mg of the pharmaceutical composition prepared in Examples 1-3 and Comparative Example 1 were weighed and added to a dialysis bag, placed in 100 mL of PBS with a pH value of 6, and the PBS temperature was adjusted to 37°C for drug release. During the drug release process, 3 mL of samples were taken at intervals of 2 hours. The absorbance of the solution was measured, and the cumulative drug release amount was calculated. At the same time, 3 mL of PBS was added to maintain the total volume of PBS unchanged, and the drug release capacity of the sample was measured. The results are shown in Table 1.
[0099] Table 1: Comparison of drug release rates of Examples 1-3 and Comparative Example 1
[0100] Cumulative drug release rate at 250h (%) Example 1 37 Example 2 38 Example 3 37 Comparative Example 1 95
[0101] from Figure 2It can be seen that the drug release trend of Example 1 is relatively gentle during the entire drug release process, indicating that the pharmaceutical composition prepared in Example 1 does not have a situation in which the carrier is cracked and destroyed under an acidic environment and the drug release is unstable, thereby being able to indicate that the pharmaceutical composition has good stability. It can be seen that sodium alginate is first dissolved in ultrapure water, calcium chloride is added as a cross-linking agent, and the hydrogel is prepared by stirring and cross-linking, and then the sophora japonica extract, chondroitin sulfate and collagen peptide are added, and fully mixed to make the sophora japonica extract, chondroitin sulfate and collagen peptide loaded in the sodium alginate hydrogel. Sodium alginate is used as a carrier of the sophora japonica extract, an active ingredient for preventing osteoporosis, to effectively improve the stability of the sophora japonica extract, and then to improve the bioavailability of the sophora japonica extract. In addition, it can be seen from Table 1 that the drug component in Comparative Example 1 has a 250h cumulative drug release rate of about 95% without carrier loading, while in Example 1 it is only 37%. It can be seen that the pharmaceutical composition prepared in Example 1 has a long action time, can reduce the number of administrations, and reduce the burden on patients.
[0102] Experiment 2:
[0103] The extract of flavonoids from Sophora japonica was labeled with FITC in advance, and then the pharmaceutical composition was prepared according to the steps of Example 1 and Comparative Example 2, respectively. Male SD rats were randomly divided into groups, 4 rats in each group, and stably fed for 1 week. The rats were starved one day before the start, and then the rats were gavaged with a gavage dose of 140 mg / kg. After gavage for 24 hours, the rats were subjected to in vivo fluorescence imaging, and then they were killed, and the femurs of the rats were cut off and fluorescence imaging was performed again. The results are as follows: Figure 3 shown.
[0104] from Figure 3 It can be seen that the signal distribution in the femur of the rats gavaged with the pharmaceutical composition prepared in Example 1 is uniform, showing an obvious high signal. It can be seen that stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and 1-hydroxybenzotriazole are mixed and dissolved in N,N-dimethylformamide to prepare a mixed solution, and then tetracycline hydrochloride is dissolved in N,N-dimethylformamide to prepare a tetracycline hydrochloride solution, and then the tetracycline hydrochloride solution is added to the mixed solution for reaction to prepare a targeting intermediate with a bone targeting effect. After the bone targeting intermediate is grafted on the sodium alginate hydrogel, the bone targeting of the sodium alginate drug-loaded hydrogel can be improved, and the problem of poor specificity of components such as the hydrogel loaded with the sophora japonica extract can be corrected, thereby enhancing osteoblast differentiation and further improving the bioavailability of the sophora japonica extract.
[0105] Experiment 3:
[0106] Thirty-six 8-week-old female mice were selected and randomly divided into a control group, Example 1 group, Comparative Example 3 group, Comparative Example 4 group, Comparative Example 5 group and Comparative Example 6 group, with 6 mice in each group. After anesthesia, the mice in each group were placed in a supine position, and a transverse incision of about 1.5 cm in length was made on the abdomen. The fallopian tubes were visible after opening the abdominal cavity, and the ovaries were found retrogradely. After the fallopian tubes were ligated, the ovaries were completely removed, and the incisions were sutured layer by layer. After resting for 1 week, the mice were given oral administration. The control group was given 2 mL of 1% sodium carboxymethyl cellulose solution, the Example 1 group was given 20 mg of the pharmaceutical composition prepared in Example 1 and 2 mL of 1% sodium carboxymethyl cellulose solution, and the Comparative Example 3 group was given 20 mg of the pharmaceutical composition prepared in Comparative Example 3 and 2 mL of 1 % sodium carboxymethyl cellulose solution, comparative example 4 group was given 20 mg of the pharmaceutical composition prepared in comparative example 4 and 2 mL of 1% sodium carboxymethyl cellulose solution, comparative example 5 group was given 20 mg of the pharmaceutical composition prepared in comparative example 5 and 2 mL of 1% sodium carboxymethyl cellulose solution, and comparative example 6 group was given 20 mg of the pharmaceutical composition prepared in comparative example 6 and 2 mL of 1% sodium carboxymethyl cellulose solution, once a day, for 8 weeks. After continuous gavage, the femur specimens of mice were collected, the muscles around the bone tissue were removed, and then the femurs were fixed in a Micro-CT sample detection plate for scanning, and the bone density, bone volume fraction and number of trabeculae were measured and the average values were taken. The results are shown in Table 2 below.
[0107] Table 2: Comparison of bone density, bone volume fraction and trabecular number of mice in the control group, Example 1 group and Comparative Examples 3-6 groups
[0108]
[0109] As can be seen from Table 2, the bone density, bone volume fraction and number of trabeculae of mice in Example 1, Comparative Example 3 and Comparative Example 5-6 groups were significantly higher than those in the control group; while the bone density, bone volume fraction and number of trabeculae of mice in Comparative Example 3 and Comparative Example 4 groups were lower than those in Example 1. It can be seen that the Sophora japonica extract can intervene in the Wnt / β-catenin signaling pathway to regulate the amount of β-catenin and the formation of the β-catenin-TCF / LEF complex, promote the production of BMP bone morphogenetic protein and osteoblast proliferation and differentiation, and inhibit osteoclast formation, while chondroitin sulfate can help maintain the lubricity and elasticity of joints, affect the metabolism of bone cells, protect bone tissue, increase bone mineral content and bone density, promote osteoblast proliferation and new bone formation, and the compounding of Sophora japonica extract and chondroitin sulfate has a synergistic effect to prevent the risk of osteoporosis;
[0110] In addition, the bone density, bone volume fraction and number of trabeculae of the mice in Comparative Example 5 and Comparative Example 6 were also lower than those in Example 1. This shows that the addition of collagen peptides can interact with chondroitin sulfate and help accelerate the regeneration of damaged cartilage.
[0111] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A process for preparing a pharmaceutical composition for preventing osteoporosis, characterized in that: The steps include: S1: Preparation of Sophora japonica flavonoids extract The sophora japonica seed is washed, dried, and crushed, and then added to a methanol solution, and then hydrochloric acid is added to perform ultrasonic assisted reflux extraction, and after filtering, the filter residue is repeatedly extracted once, and the filtrate is combined and evaporated and concentrated to obtain the sophora japonica seed flavonoids extract; S2: Pretreatment of sturgeon The sturgeon segments are thawed, the meat is removed, the head, spinal cord and fin cartilage are taken out, and they are immersed in 80-100°C water for 5-10 minutes, then taken out and cooled to 30-40°C, the muscles, fat and other connective tissues remaining on the head, spinal cord and fin cartilage are removed, and then they are minced with a meat grinder, put into water and stirred, and sieved, washed and dried to obtain pre-treated aggregates; S3: Preparation of chondroitin sulfate and collagen peptides The pretreated aggregate is mixed with deionized water for grinding, and then heated. After cooling, sodium carbonate is added to adjust the pH, and then alkaline protease, papain and bromelain are added in sequence for enzymolysis. After the enzymes are inactivated, chondroitin sulfate and collagen peptides are obtained by filtering, ultrafiltration and freeze drying. S4: Preparation of targeted intermediates Mixing stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide, heating and dissolving them to prepare a mixed solution, then dissolving tetracycline hydrochloride to prepare a tetracycline hydrochloride solution, then adding the tetracycline hydrochloride solution to the mixed solution, reacting, dialyzing, centrifuging, washing and drying to obtain a targeted intermediate; S5: Preparation of pharmaceutical composition The targeting intermediate is dissolved in ethanol to prepare a targeting intermediate solution, sodium alginate is dissolved in ultrapure water, a calcium chloride solution is added and stirred to prepare a sodium alginate mixed solution, the sophora japonica flavonoids extract, the chondroitin sulfate and the collagen peptide are added to the sodium alginate mixed solution, the targeting intermediate solution is added, the mixture is heated and stirred, and then the gelatin liquid is separated, freeze-dried and ground to obtain a pharmaceutical composition.
2. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 1, characterized in that: S1 specifically includes the following steps: S1.1: Wash and dry the Sophora japonica seeds, and then place them in a grinder to fully grind them to obtain Sophora japonica seeds powder; S1.2: Add the above-mentioned Sophora japonica powder to 60% methanol solution at a solid-liquid ratio of 1g: (90-100)mL, stir and mix evenly, and then add hydrochloric acid at 0.01-0.03mmol / L to obtain an extract; S1.3: The above extract is heated to 60-70°C for 20-30 minutes and then subjected to ultrasonic-assisted reflux extraction for 1-2 hours. After cooling, it is filtered and the residue is repeatedly extracted once. The filtrates are combined and the combined filtrates are placed in a rotary evaporator for evaporation and concentration to obtain the sophora japonica flavonoids extract.
3. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 2, characterized in that: S3 specifically includes the following steps: S3.1: Mix the pretreated aggregate obtained in step S2 with deionized water in a mass ratio of 1:(4-6) and grind into a slurry, then heat at 90-100°C for 20-30min, and when the temperature drops to 25-30°C, add sodium carbonate to adjust the pH to 8-9 to obtain a mixed slurry; S3.2: add alkaline protease to the mixed slurry, heat at 40-45°C for 1-2h, then add papain, heat at 45-50°C for 1-2h, then add bromelain, heat at 45-50°C for 1-2h, then heat to 90-95°C, inactivate the enzyme for 20-30min, and obtain an enzymolysis solution; S3.3: The above enzymatic hydrolysate is filtered, and the filtrate is ultrafiltered using a hollow fiber membrane with a molecular weight cutoff of 10,000 Da. The retained portion is freeze-dried to obtain chondroitin sulfate, and the permeate is freeze-dried to obtain collagen peptides.
4. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 3, characterized in that: S4 specifically includes the following steps: S4.1: Add stearic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole and N,N-dimethylformamide into a reactor at a solid-liquid ratio of (1.4-2) g: (1.5-1.9) g: 1 g: (130-150) mL, heat and stir at 40-50 ° C for 1-2 h to fully dissolve, and then keep warm for 20-30 min to obtain a mixed solution; S4.2: Dissolve tetracycline hydrochloride in N,N-dimethylformamide at a solid-liquid ratio of 1 g:(20-30) mL to obtain a tetracycline hydrochloride solution; S4.3: Add the above-mentioned tetracycline hydrochloride to the above-mentioned mixed solution, react for 20-24 hours under a nitrogen atmosphere, and then place it in a dialysis bag for dialyzing for 48-50 hours. Take out the suspension in the dialysis bag and place it in a centrifuge. Centrifuge at a rate of 4000-5000r / min for 8-10min, collect the precipitate, wash and dry it to obtain a targeted intermediate.
5. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 4, characterized in that: S5 specifically includes the following steps: S5.1: Add the targeted intermediate prepared in step S4.3 to ethanol at a solid-liquid ratio of 1 g: (10-12) mL, and stir until completely dissolved to obtain a targeted intermediate solution; S5.2: Dissolve sodium alginate in ultrapure water at a solid-liquid ratio of 1 g: (60-70) mL, add calcium chloride solution, and perform ultrasonic stirring until it becomes viscous to obtain a sodium alginate mixed solution; S5.3: Add the flavonoids extract of Sophora japonica obtained in step S1.3, chondroitin sulfate and collagen peptide obtained in step S3.3 to the above-mentioned sodium alginate mixed solution, stir and mix evenly, then add the above-mentioned targeted intermediate solution at a mass ratio of targeted intermediate to sodium alginate of 1:(8-12), heat and stir at 30-40°C for 12-14h, separate the gel solution, and obtain a composite gel; S5.4: Place the above composite gel in a freeze dryer for freeze drying, and then place it in a grinder for grinding to obtain a pharmaceutical composition.
6. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 3, characterized in that: The dosage of alkaline protease is 200U / g, the dosage of papain is 100U / g, and the dosage of bromelain is 30U / g.
7. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 4, characterized in that: The mass ratio of tetracycline hydrochloride to stearic acid is (1.3-1.5):
1.
8. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 5, characterized in that: The concentration of the calcium chloride solution is 1-3%, and the volume ratio of the calcium chloride solution to ultrapure water is 1:(25-35).
9. The preparation process of a pharmaceutical composition for preventing osteoporosis according to claim 5, characterized in that: The mass ratio of the flavonoids extract from Sophora japonica, chondroitin sulfate and collagen peptide is (6-8):(3-5):1, and the mass ratio of the flavonoids extract from Sophora japonica to sodium alginate is 1:(20-30).
10. A pharmaceutical composition for preventing osteoporosis, characterized in that: It is prepared by the preparation process of a pharmaceutical composition for preventing osteoporosis according to any one of claims 1 to 9.
Citation Information
Patent Citations
Osteoporosis patient full nutrition formula food and preparation method thereof
CN105105106A
Stearic acid grafted tetracycline, and preparation and application thereof
CN105884633A
Bone-targeting drug-loaded system and preparation method thereof
CN108939085A
Application of sodium alginate hydrogel nano-carrier in whitening cream
CN111407681A
Preparation method of bone extract and application of bone extract to osteoporosis and osteoarthritis
CN112245452A
Cited By
Health-care wine containing ginkgo biloba extract and preparation method of health-care wine
CN120025885A
Bone peptide composition for osteoporosis repair and preparation method thereof
CN120053592A
A kind of osteopeptide composition for repairing osteoporosis and preparation method thereof
CN120053592B
Bovine bone microcapsule with intestinal tract targeting property as well as preparation method and application thereof
CN121621540A
Injectable in-situ cross-linking hydrogel of rare earth doped carbon quantum dots and application of injectable in-situ cross-linking hydrogel
CN122351581A
